A small‐molecular inhibitor targeting KAT6A increases the efficacy of anti‐PD‐L1 therapy by inhibiting TNBC metastasis and significantly prolongs the survival for tumor xenograft‐bearing animals. This evidence concerns the gene CD274 and neoplasm.